[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647517":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":10,"responsibleParty":31,"collaborators":10,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":51,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":10},{"fullName":5,"class":6},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"IPMN Cohort",null,"Adult patients undergoing pancreatic resection with histopathologic diagnosis of intraductal papillary mucinous neoplasm (IPMN); residual tumor tissue and, when available, adjacent non neoplastic tissue will be collected for molecular analyses and organoid generation",{"label":13,"type":10,"description":14,"interventionNames":10},"PanIN Cohort","Adult patients undergoing pancreatic resection with histopathologic diagnosis of pancreatic intraepithelial neoplasia (PanIN); residual tissue will be used for genomic, transcriptomic, proteomic, and functional studies in patient derived models",{"label":16,"type":10,"description":17,"interventionNames":10},"PDAC Cohort","Adult patients undergoing pancreatic resection with histopathologic diagnosis of pancreatic ductal adenocarcinoma (PDAC); biospecimens will be processed for comprehensive molecular characterization and comparison with precursor lesions",[19],{"name":20,"affiliation":21,"role":22},"Raffaele Armentano, MD","IRCCS \"Saverio de Bellis\"","PRINCIPAL_INVESTIGATOR",[24,28],{"name":20,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","+390804994185","raffaele.armentano@irccsdebellis.it",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Martina Lepore Signorile, Biologist","martina.lepore@irccsdebellis.it",{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100647517","predictive-biomarkers-for-early-diagnosis-of-pancreatic-ductal-adenocarcinoma-pdac-100647517",false,"NCT07709052","Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)","B-PDAC","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients undergoing pancreatic surgical resection for suspected pancreatic neoplasm.\n* Histopathologic diagnosis of intraductal papillary mucinous neoplasm (IPMN), pancreatic intraepithelial neoplasia (PanIN), or pancreatic ductal adenocarcinoma (PDAC).\n* Availability of residual tumor tissue from the surgical procedure not required for diagnostic purposes.\n* Signed written informed consent for the use of biological samples for research purposes\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Surgical procedure performed for neoplasms other than IPMN, PanIN, or PDAC.\n* Absence of written informed consent.","ALL","18 Years",{"count":43,"type":44},180,"ESTIMATED","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates. Many PDACs arise from non-invasive precursor lesions that develop over years, including pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMN). Only a minority of pancreatic cystic lesions progress to invasive carcinoma, and current clinical and radiologic criteria have limited accuracy in predicting which patients are at high risk. This observational translational study will enroll adult patients undergoing pancreatic surgical resection for suspected pancreatic neoplasm (IPMN, PanIN, or PDAC) at IRCCS \"Saverio de Bellis\". Residual tumor tissue not required for diagnostic purposes, and when available adjacent non-neoplastic tissue, will be collected, coded, and pseudonymized for molecular analyses. Tumor cells will be used to generate three-dimensional cultures (tumorspheres and organoids) and will undergo genomic characterization by next-generation sequencing, RNA-sequencing-based transcriptomic profiling, protein expression analyses, advanced imaging, and in-vitro drug response assays. The main goal is to identify and validate molecular biomarkers predictive of progression to PDAC, improve risk stratification of patients with pancreatic precursor lesions, and support the development of innovative precision medicine strategies.",[48,49,50],"Pancreatic Ductal Adenocarcinoma (PDAC)","Intraductal Papillary Mucinous Neoplasm of Pancreas","Pancreatic Intraepithelial Neoplasia",[52,53,54],"PDAC","IPMN","PanIN","NOT_YET_RECRUITING","2026-07-13",{"date":58,"type":59},"2026-07-16","ACTUAL",{"date":61,"type":44},"2026-09-01",{"date":63,"type":44},"2028-09-01",{"name":5,"class":6}]